Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.

We have previously reported that serum interleukin-18 (IL-18) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). When rituximab (R) was added to this regimen, the prognosis of diffuse large B-cell lymphoma (DLBCL) was markedly improved.
In this study, we re-evaluated the prognostic significance of serum IL-18 in 227 DLBCL patients. Seventy-three patients received CHOP before R-era, and 154 patients received rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) recently.
Four-year overall survival (4-yr OS) rates for patients in CHOP group with IL-18 ≥720 pg/mL and <720 pg/mL were 8.2% and 67.3% (P<0.0001), respectively, and 4-yr OS rates with IL-18 ≥590 and <590 pg/mL in R-CHOP group were 53.4% and 77.8% (P=0.0008), respectively. Multivariate analysis revealed that serum IL-18 correlated most significantly with OS and progression-free survival (PFS) in both groups (OS: P<0.0001, PFS: P<0.0001, in CHOP group; OS: P=0.0147, PFS: P=0.0084 in R-CHOP group). The high serum IL-18 patients with poor prognostic group in revised IPI or with non-germinal center B-cell phenotype had a very poor prognosis.
Serum IL-18 might be a powerful prognostic factor for DLBCL in R-era.
AuthorsNaoe Goto, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Nobuo Murakami, Michio Sawada, Toshiki Yamada, Masao Takemura, Mitsuru Seishima, Yusuke Kito, Tsuyoshi Takami, Hisataka Moriwaki
JournalEuropean journal of haematology (Eur J Haematol) Vol. 87 Issue 3 Pg. 217-27 (Sep 2011) ISSN: 1600-0609 [Electronic] England
PMID21575062 (Publication Type: Journal Article)
Copyright© 2011 John Wiley & Sons A/S.
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Interleukin-18
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cyclophosphamide (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Female
  • Humans
  • Interleukin-18 (blood)
  • Lymphoma, Large B-Cell, Diffuse (drug therapy, mortality, pathology)
  • Male
  • Middle Aged
  • Prednisone (therapeutic use)
  • Prognosis
  • Rituximab
  • Survival Analysis
  • Vincristine (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: